NexGen Medical Systems, Inc., a US medical device company, has announced the successful completion of the first human use of their XCOIL large vessel (18mm) thrombectomy system for the treatment of deep vein thrombosis (DVT). The new device, an expansion of the XCOIL 12mm System, is designed to rapidly remove blood clots in large vessels, such as the iliac vein.
The company’s thrombectomy systems are comprised of an encapsulator sheath and a retractor catheter. The retractor is used to engage and extract the clot, pull it into the encapsulator and remove the clot from the body, while minimising the need for clot-dissolving lytic drugs.
“This expansion of the XCOIL platform provides our customers with an effective portfolio of solutions for the many patients suffering from deep vein thrombosis in the USA,” said Denis Harrington, president and chief executive officer of NexGen Medical Systems. “With the successful addition of our large vessel solution, NexGen Medical continues to demonstrate our commitment to developing advanced solutions for treating DVT blood clots and in the future expanding our platforms to treat pulmonary embolism clots.”
David Buechner (Methodist Hospital, Memphis, USA), shared, “Our therapeutic goal is to rapidly restore blood flow by removing the clot, quickly and safely, while minimising the need for clot-dissolving drugs which are not appropriate for all patients and can have negative side effects. The XCOIL thrombectomy system provides a rapid mechanical solution and may improve outcomes, and reduce costs, for our patients.”
The impact of blood clots can range from deep vein thrombosis to pulmonary embolisms and strokes. Blood clots account for more deaths each year than breast cancer, road traffic accidents, and AIDS combined.
